Arvinas, Pfizer Find New Partner for ‘Protac’ Breast Cancer Drug

Arvinas and Pfizer License PROTAC Breast Cancer Drug Veppanu to Rigel

Arvinas and Pfizer have completed a licensing deal to transfer ownership of their recently approved breast cancer drug, Veppanu, to Rigel Pharmaceuticals. The agreement includes an upfront payment of $75 million, an additional $15 million upon completion of transition activities, and potential future milestone payments of up to $320 million, along with sales royalties. Rigel Pharmaceuticals will gain global rights to Veppanu, which received U.S. approval earlier this month as the first PROTAC medicine. The drug is indicated for certain estrogen receptor-positive breast cancer patients with ESR1 mutations. This transaction allows Arvinas to focus on its other pipeline assets, while Rigel aims to establish Veppanu as a significant revenue driver.

• The licensing agreement between Arvinas, Pfizer, and Rigel Pharmaceuticals includes substantial financial terms. Arvinas and Pfizer will receive $75 million upfront, an additional $15 million after specific transition activities, and are eligible for up to $320 million in future milestone payments. The deal also grants them sales royalties on Veppanu, while Rigel secures global rights to the drug, including the flexibility to partner for non-U.S. markets.
• Veppanu, previously known as vepdegestrant, recently achieved a significant milestone by becoming the first PROTAC (protein-trashing medicine) to gain U.S. market approval. It is specifically cleared for the treatment of certain individuals with estrogen receptor-positive breast cancer who possess mutations to the ESR1 gene, where the drug demonstrated its most pronounced benefits.
• The decision by Arvinas and Pfizer to offload Veppanu stems from a strategic re-evaluation of its commercial potential. Despite its novel mechanism, the drug's efficacy was most evident in a specific patient subpopulation (ESR1-mutated breast cancer), and its clinical data did not clearly differentiate it from other recently approved hormone-degrading cancer therapies. This transaction allows Arvinas to streamline its pipeline and focus on other programs, while Rigel expands its oncology portfolio with a drug featuring a novel mechanism of action.

The Unmet Needs Driving Innovation in ESR1-Mutated Breast Cancer

Estrogen receptor-positive breast cancer with ESR1 mutations presents significant therapeutic challenges that limit the effectiveness of current treatment approaches. These mutations, which occur in 10-50% of metastatic, endocrine therapy-resistant cases compared to only ~1% in primary tumors, drive resistance mechanisms that compromise standard endocrine therapies. The complexity of the post-treatment genomic landscape, influenced by CDK4/6 inhibitor exposure, further complicates optimal therapeutic selection.

• Endocrine resistance represents the primary treatment barrier, necessitating a transition from less toxic endocrine therapies to more aggressive treatment regimens in patients with ER+/HER2- metastatic breast cancer

• ESR1 mutations confer significantly shortened progression-free survival on aromatase inhibitor treatment, with mutation carriers experiencing markedly worse outcomes (p = 0.017) compared to wild-type patients

• Heterogeneous treatment responses occur even within ESR1 mutant subgroups, with oral selective ER degraders showing variable efficacy despite the presence of endocrine therapy resistance-associated mutations

• Traditional endocrine therapies demonstrate poor efficacy against ER mutants, as Y537S and D538G mutations produce an ERα with substantially higher transcriptional activity than wild-type receptors in estradiol-absent conditions

• The combination of low ER activity and high circulating tumor DNA burden predicts rapid clinical progression, creating a particularly challenging patient subset requiring intensive monitoring and alternative therapeutic approaches

• Detection and monitoring limitations may underestimate mutation prevalence, as the technical challenges of metastatic biopsies could lead to underreporting of ESR1 mutation frequency in clinical practice

• Complex resistance mechanisms involve tumor-microenvironment crosstalk, playing crucial roles in both endocrine therapy resistance and metastatic progression that current therapies inadequately address

• Visceral metastases show higher mutation rates (25% vs 6.7% in non-visceral sites), with 4.66-fold higher odds of harboring ESR1 mutations, indicating site-specific therapeutic challenges

Veppanu's Position in the Evolving ESR1-Mutated Breast Cancer Landscape

The treatment landscape for ER-positive breast cancer with ESR1 mutations has been fundamentally transformed over the past five years through the emergence of novel oral selective estrogen receptor degraders (SERDs). Elacestrant has established itself as the most significant advance, demonstrating excellent activity against ESR1 mutations associated with resistance to first-line endocrine therapies across pivotal clinical trials including the RAD1901-005 Trial, EMERALD TRIAL, ELIPSE, and ELEVATE studies. The agent showed improved progression-free survival in patients with advanced ER+/HER2-, ESR1-mutated breast cancer while maintaining a tolerable safety profile. Its oral bioavailability represents a significant advantage over injectable SERDs, with important implications for patient adherence and quality of life. The FDA and European Medicines Agency have now approved elacestrant for patients harboring ESR1 mutations, marking a critical milestone in targeted therapy for this resistant population.

The therapeutic pipeline has expanded beyond traditional SERD approaches to include innovative combination strategies and novel targets. Lasofoxifene demonstrated anti-tumor activity in the phase 2 ELAINE 1 and 2 studies, both as monotherapy and in combination with abemaciclib, leading to the ongoing phase 3 ELAINE 3 trial (NCT05696626) comparing lasofoxifene/abemaciclib versus fulvestrant/abemaciclib in 500 patients with locally advanced or metastatic ER+/HER2- breast cancer. Additionally, next-generation agents like giredestrant have shown superior efficacy against mutant ERα compared to standard-of-care agents, while zotatifin, a selective eIF4A inhibitor, has demonstrated activity through a novel mechanism targeting ER translation, with clinical responses observed when combined with fulvestrant or fulvestrant plus abemaciclib.

The clinical understanding of ESR1 mutations has become increasingly sophisticated, revealing their prevalence in up to 26.8% of metastatic HR+/HER2- breast cancer samples compared to only 3.7% in local/regional disease. Recent genomic analyses have identified important co-alterations, with 43% of patients harboring activating ESR1 mutations and 20% showing co-mutations in PIK3CA and other genes. The development of predictive tools like the SET index, which measures gene expression correlated with hormone receptors, has shown promise in predicting treatment outcomes, with higher SET index scores associated with prolonged sensitivity to endocrine therapy, particularly in the absence of mutated ESR1 transcript. These advances collectively represent a shift toward more personalized treatment strategies that integrate targeted agents with traditional therapies based on molecular characterization of individual tumors.

First PROTAC Approval: Reshaping ER+ Breast Cancer Treatment and TPD Landscape

The recent licensing agreement for Veppanu, the first FDA-approved PROTAC medicine, marks a significant inflection point for both targeted protein degradation (TPD) technology and the treatment landscape for estrogen receptor-positive (ER+) breast cancer. This transaction, transferring global rights from Arvinas and Pfizer to Rigel Pharmaceuticals, underscores the growing confidence in PROTACs as a novel therapeutic modality.

For Rigel, this acquisition is transformative. It immediately establishes the company with a pioneering asset in a high-value oncology segment, offering a clear path to substantial revenue generation. The drug's approval, specifically for ER+ breast cancer patients with ESR1 mutations, addresses a critical area of unmet need where endocrine resistance often limits treatment options. The oral administration of Veppanu also provides a distinct advantage over injectable selective estrogen receptor degraders (SERDs) like fulvestrant, potentially enhancing patient adherence and quality of life.

However, the path forward is not without considerations. While Veppanu demonstrated significantly longer progression-free survival in the ESR1-mutated subgroup, its efficacy in the broader ER+/HER2- advanced breast cancer population was not statistically superior to fulvestrant. This suggests market adoption may be concentrated within the specific ESR1-mutated patient segment. Furthermore, clinical data indicated a slightly higher incidence of Grade 3 or higher adverse events and treatment discontinuations with Veppanu compared to fulvestrant, a factor that will undoubtedly be weighed by clinicians.

Beyond Veppanu, this approval serves as a powerful validation for the entire PROTAC platform. It signals to the industry that the challenges associated with this technology—such as ensuring metabolic stability and mitigating off-target effects—are surmountable, paving the way for accelerated development of PROTACs against a wider array of previously "undruggable" targets. Rigel's success with Veppanu could therefore catalyze further innovation and investment across the TPD space, potentially reshaping future therapeutic strategies in oncology and beyond. The strategic focus for Rigel will now be on maximizing market penetration within the ESR1-mutated population and exploring combination therapies, which existing evidence suggests hold considerable promise.